Skip to main content

ponvory

Generic: ponesimod

ponvory: sourced relationships with 1 company · 1 FDA decision.

ponvory evidence translation

What we can confirm

What it means

Source-backed records connect ponvory to VNDA; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could ponvory → VNDA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (1)
CompanyDated record stage
Vanda Pharmaceuticals Inc. (VNDA)
Reported 2021-03-18 · Current development: unknownSource
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )(VNDA)FDA ↗
NDA213498Type 1 - New Molecular EntityStandardOralTablet

Frequently asked questions

Which companies have sourced relationships with ponvory?

ponvory has dated SEC/FDA relationship records for Vanda Pharmaceuticals Inc..

What is ponvory's latest FDA decision?

The most recent tracked FDA decision for ponvory is Approval for 1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 ), dated March 18, 2021.